Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2020; 26(41): 6304-6321
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6304
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6304
Efficacy and safety of anti-hepatic fibrosis drugs
Konstantinos Damiris, Department of Medicine, Rutgers-New Jersey Medical School, Newark, NJ 07103, United States
Zaid H Tafesh, Nikolaos Pyrsopoulos, Medicine-Gastroenterology and Hepatology, Rutgers-New Jersey Medical School, Newark, NJ 07103, United States
Author contributions: Damiris K and Pyrsopoulos N equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision/editing; Tafesh ZH contributed with literature review, drafting and critical revision/editing; all authors have read and approve the final manuscript.
Conflict-of-interest statement: The authors do not have any conflicts of interest relevant to this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nikolaos Pyrsopoulos, FACP, MD, PhD, Director, Doctor, Professor, Medicine-Gastroenterology and Hepatology, Rutgers-New Jersey Medical School, 185 S. Orange Avenue, MSB H-535, Newark, NJ 07103, United States. pyrsopni@njms.rutgers.edu
Received: August 3, 2020
Peer-review started: August 3, 2020
First decision: September 12, 2020
Revised: September 30, 2020
Accepted: October 20, 2020
Article in press: October 20, 2020
Published online: November 7, 2020
Processing time: 94 Days and 9.2 Hours
Peer-review started: August 3, 2020
First decision: September 12, 2020
Revised: September 30, 2020
Accepted: October 20, 2020
Article in press: October 20, 2020
Published online: November 7, 2020
Processing time: 94 Days and 9.2 Hours
Core Tip
Core Tip: A number of clinical trials have targeted various etiologies of liver fibrosis and cirrhosis. Some have been promising, particularly in metabolic associated fatty liver disease and viral hepatitis. Results from these studies have shown that there are safe treatments available, forming currently practiced therapeutic guidelines, and shining light on the potential reversibility of liver fibrosis and cirrhosis caused by a variety of etiologies.